1	Exp tumor necrosis factor alpha antibody/
2	Exp tumor necrosis factor antibody/
3	Tumo?r necrosis factor antagonist.Mp.
4	Tumo?r necrosis factor alpha antagonist.Mp.
5	Exp tumor necrosis factor alpha inhibitor/
6	Anti tumo?r necrosis factor.Mp.
7	Anti tumo?r necrosis factor alpha.Mp.
8	(anti‐TNF or anti‐TNF alpha).m_titl.
9	Adalimumab/
10	Certolizumab pegol/
11	Etanercept/
12	Infliximab/
13	Golimumab/
14	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15	Arterial stiffness/
16	Exp artery compliance/
17	Arter* function.Mp.
18	Exp pulse wave/
19	Pulse wave velocity.Mp.
20	Pulse wave analysis.Mp.
21	Exp augmentation index/
22	Endothelial dysfunction/
23	Endotheli* function*.Mp.
24	Exp vasodilatation/
25	Flow mediated dilat*.Mp.
26	Exp blood vessel compliance/
27	Vascular compliance.Mp.
28	Exp carotid intima media thickness/
29	Carotid intima media thick*.Mp.
30	Intima media thick*.Mp.
31	15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32	(chronic disease* adj2 inflammat*).Mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
33	Chronic inflammatory disease*.Mp.
34	Exp rheumatoid arthritis/
35	Exp psoriatic arthritis/
36	Exp ankylosing spondylitis/
37	Inflammatory bowel disease*.Mp.
38	Exp Crohn disease/
39	Colitis/or exp ulcerative colitis/
40	Exp enteritis/
41	Chronic inflammatory skin disease*.Mp.
42	Exp dermatitis/
43	Psoriasis vulgaris/or psoriasis/
44	Bullous skin disease/or bullous pemphigoid/
45	Exp vasculitis/
46	Exp systemic lupus erythematosus/
47	Exp chronic obstructive lung disease/
48	Chronic obstructive pulmonary disease.Mp.
49	Exp chronic bronchitis/
50	32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49
51	14 and 31 and 50